Editas Medicine, Inc. Common Stock
$2.71
$0.08 (+3.04%)
$2.63Day Range$2.73
Key Statistics
Market Cap
$416.20M
Shares Outstanding
153.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 3, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$2.65
Day High
$2.73
Day Low
$2.63
Volume
2.49M
VWAP
$2.70
Prev Close
$2.63
Transactions
--
Acc. Volume
--
About Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283687 employees11 HURLEY ST., CAMBRIDGE, MA, 02141617-401-9000IPO Feb 3, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001650664
- Composite FIGI
- BBG005MX5GZ2
- Share Class FIGI
- BBG005MX5H08
- Ticker Root
- EDIT
- SIC Code
- 2836
About Editas Medicine, Inc. Common Stock (EDIT) Stock
Editas Medicine, Inc. Common Stock (EDIT) closed the 2026-09-16 session at $2.71, up 3.04% versus the previous close (+0.08). The stock opened at $2.65 and traded between $2.63 and $2.73 during that session. Session trading volume was 2.5M shares. The volume-weighted average price (VWAP) is $2.70.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Editas Medicine, Inc. Common Stock has a market capitalization of $416.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. EDIT is listed on the XNAS exchange. The company employs approximately 87 people. Editas Medicine, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2016-02-03.
On this page you can find market EDIT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.